Atazanavir/Ritonavir

DRUG13 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Germans Trias i Pujol Hospital, Bristol-Myers Squibb, International Antiviral Therapy Evaluation Center, Massachusetts General Hospital

Conditions

Drug InteractionHIVHIV InfectionHIV InfectionsHepatitis CLipodystrophyMitochondrial DysfunctionWasting Disease

Phase 1

Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV

CompletedNCT00307502

Germans Trias i Pujol HospitalHIV Infections

Start: 2005-01-31End: 2009-12-31Updated: 2019-12-04

Drug Interaction Study With Proton Pump Inhibitor

CompletedNCT00357240

Bristol-Myers SquibbHIV Infections

Start: 2006-06-30End: 2006-08-31Target: 56Updated: 2011-04-08

Phase 3

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

CompletedNCT01003990

Bristol-Myers SquibbHIV

Start: 2002-10-31End: 2016-02-29Updated: 2017-05-11

Phase 4

Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients

CompletedNCT00384904

Bristol-Myers SquibbHIV Infections

Start: 2006-12-31End: 2007-12-31Updated: 2010-02-05

BASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes

CompletedNCT00389402

International Antiviral Therapy Evaluation CenterHIV Infections

Start: 2006-07-31End: 2008-07-31Target: 120Updated: 2010-06-11

The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects

CompletedNCT00540137

Imperial College LondonHIV Infections

Start: 2007-07-31End: 2012-12-31Updated: 2014-05-21

Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users

St. James's Hospital, IrelandHepatitis C, HIV Infections

Start: 2010-08-31End: 2012-12-31Target: 40Updated: 2011-07-21

Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression

TerminatedNCT01194856

The Cleveland ClinicHIV Infection, Mitochondrial Dysfunction

Start: 2010-10-31End: 2011-12-31Updated: 2017-08-11

Safety Study of Raltegravir in HIV/HCV Co-infected Patients

WithdrawnNCT01225705

University Hospital, BonnHepatitis C, HIV

Start: 2010-10-31End: 2012-08-31Updated: 2015-06-03

Switch to Unboosted Atazanavir With Tenofovir Study

CompletedNCT01351740

University of British ColumbiaHIV Infection

Start: 2011-07-31End: 2015-12-31Updated: 2018-07-30

Unknown Phase

Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients

CompletedNCT00028314

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, Lipodystrophy, Wasting Disease

Start: 2002-03-31End: 2005-03-31Target: 150Updated: 2013-07-29

Metabolic Effects of Switching Kaletra to Boosted Reyataz

CompletedNCT00413153

Massachusetts General HospitalHIV Infections

Start: 2006-05-31End: 2008-12-31Updated: 2010-03-09

Pharmacokinetic Interaction Between Nitazoxanide and Atazanavir/Ritonavir in Healthy Volunteers

CompletedNCT05680792

Obafemi Awolowo UniversityDrug Interaction

Start: 2020-09-10End: 2023-01-31Updated: 2023-09-13

Related Papers

Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.

2009-03-1918 citations